CannBioRx Life Sciences (ATNFW) has had the highest return since August 1, 2025 by a micro-cap US stock, returning 3,259.4%.
| ASSET | % RETURN |
|---|---|
CannBioRx Life Sciences (ATNFW) | 3,259.38% |
BioXcel Therapeutics (BTAI) | 241.57% |
Equillium (EQ) | 235% |
Bolt Projects (BSLK) | 180.8% |
Cognition Therapeutics (CGTX) | 168.23% |
Advent Technologies (ADN) | 133.87% |
Trinity Biotech (TRIB) | 124.29% |
Thayer Ventures Acquisition (TVACW) | 113.14% |
Matinas BioPharma (MTNB) | 101.18% |
Real Messenger Corporation Ordinary Shares (RMSG) | 93.18% |
Ovid Therapeutics (OVID) | 91.19% |
Dogness International Corp Class A (DOGZ) | 89.45% |
Soligenix (SNGX) | 86.47% |
Fossil (FOSL) | 86.14% |
Perfect Moment (PMNT) | 83.61% |
Sonoma Pharmaceuticals (SNOA) | 83.22% |
Tenaya Therapeutics (TNYA) | 82.61% |
Burning Rock Biotech (BNR) | 78.42% |
mF International Limited Ordinary Shares (MFI) | 76.78% |
Alx Oncology Holdings (ALXO) | 76.53% |
CASI Pharmaceuticals (CASI) | 75.19% |
Zivo Bioscience (ZIVO) | 75.09% |
InfuSystems (INFU) | 72.96% |
Kindly (NAKA) | 70.98% |
Evoke Pharma (EVOK) | 70.29% |
Micro-cap stocks are treated as having a market cap of <= $300M.
